Skip to content
OpenCapital
Get started

Innovate VATE Life Sciences — SG&A

Other segment segments

Infrastructure
$32M+9.2%
Spectrum
$1.7M-10.5%

Other financials

Income statement

See full
Revenue$364.8M+33.0%
Gross profit$53.5M+17.6%
Operating income$10.0M+194%
Net income-$16.8M+31.4%
EPS (diluted)-$1.29+31.7%

Balance sheet

See full
Cash & equivalents$134.6M+297%
Total debt$1.4B+11.6%
Total equity-$256.3M-25.5%
Total assets$936.8M+7.9%

Cash flow

See full
Operating cash flow$45.5M+423%
CapEx$200.0K-95.7%
Free cash flow$45.3M+341%

Valuation

See full
Market cap$254.69M+274%

Where this comes from

Reported directly by Innovate in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Innovate’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innovate's life sciences — sg&a.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innovate's life sciences — SG&A?
Innovate (VATE) reported life sciences — SG&A of $2.3M in Q1 2026.
How has Innovate's life sciences — SG&A changed year-over-year?
Innovate's life sciences — SG&A decreased by 37.8% year-over-year, from $3.7M to $2.3M.
What is the long-term trend for Innovate's life sciences — SG&A?
Over 2 years (2023 to 2025), Innovate's life sciences — SG&A has grown at a -2.0% compound annual growth rate (CAGR), from $15.2M to $14.6M.
What does life sciences — SG&A mean?
This reflects the overhead costs associated with operating the Life Sciences segment, including marketing, sales, and general corporate support functions. It is used to evaluate the segment's operational cost structure and administrative efficiency.